Market Research Report
Soft Tissue Sarcoma (STS) with lung metastases - Market Insights, Epidemiology, and Market Forecast-2030
|Soft Tissue Sarcoma (STS) with lung metastases - Market Insights, Epidemiology, and Market Forecast-2030|
DelveInsight Business Research LLP
Content info: 108 Pages
Delivery time: 2-10 business days
DelveInsight's 'Soft Tissue Sarcoma (STS) with lung metastases-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the STS with lung metastases, historical and forecasted epidemiology as well as the STS with lung metastases market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The STS with lung metastases market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM STS with lung metastases market size from 2017 to 2030. The Report also covers current STS with lung metastases treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
STS with lung metastases Overview
Soft tissue sarcoma is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). These cancers can develop anywhere in the body but are found mostly in the arms, legs, chest, and abdomen. For patients with STS, the lungs are the most common site of metastatic disease. Although pulmonary metastases most commonly arise from primary tumors in the extremities, they may arise from almost any primary site or histology. It was also analyzed that, approximately 20-25% of all STS patients will develop pulmonary metastases (40-60% for high-grade tumors), which will become clinically evident usually in the first 2 years following diagnosis. For extremity STS, radiotherapy, in addition to surgical removal of the tumor has been shown to reduce the risk of local recurrence, but it has no impact on survival. However, guidelines for the performance of pulmonary metastasectomy for STS do not exist, and decisions to operate are often made on an individual basis. Up to half of the STS, patients develop one or more lung metastases. Without effective systemic therapies, doctors often rely on pulmonary metastasectomy, surgical removal of the pulmonary metastases, although current data for the practice specific to STS are limited. Lung metastasis produces symptoms similar to those of other serious lung or chest ailments. It is possible, however, for lung metastases to present no symptoms at all. Sometimes the cancerous growth is discovered by accident when the doctor takes a chest x-ray of the patient for other reasons
STS with lung metastases Diagnosis
The diagnosis of STS are mainly made by doing Imaging tests and by biopsy; however, the test is done after signs and symptoms occur. A regular x-ray of the area with the lump may be the first test ordered. A chest x-ray may be done after diagnosis to see if the sarcoma has spread to the lungs. A CT scan uses x-rays to make detailed cross-sectional images of the body. This test is also used to see if the sarcoma has spread to the lungs, liver, or other organs.
Continued in the report…..
STS with lung metastases Treatment
Metastases is a type of lung tumor that develops when cancer from another body site. When this occurs, the tumors in the lung are referred to as metastatic lung (pulmonary) tumors. Because it acts as a sieve for all of the blood that passes through the body, the lung is a very common site for metastatic tumors to lodge. Fortunately, patients with tumors that spread to the lung from other sites often still have a chance to be cured by surgical removal of these tumors, frequently in combination with chemotherapy. Early on, surgical therapy for sarcoma metastases was based on gaining adequate access and visualization to perform a complete resection, including removal of any occult or residual disease. Standard posterolateral thoracotomy provided excellent visualization and allowed the surgeon to examine the entire pleural surface. In surgery for pulmonary metastases complete resection of all lesions and preservation of lung parenchyma is of utmost importance. Pulmonary metastasectomy is performed heterogeneously not only concerning the surgical approach (open vs. VATS) but also to resection techniques (e.g., laser enucleation, electrocautery resection, stapling)
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident cases of STS (Soft tissue sarcoma),Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
The epidemiology segment also provides the STS with lung metastases epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
STS with lung metastases Emerging Drugs
Annamycin is a unique next-generation liposome formulated anthracycline (also referred to in the literature as "L-Annamycin") that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines. Annamycin was discovered by Professor Waldemar Priebe at The University of Texas MD Anderson Cancer Center. Anthracyclines are a class of chemotherapy drugs considered to be among the most effectively available, and with a broader spectrum of anticancer activity than most other classes of chemotherapeutic agents. They have been recognized for their pleiotropic (producing or having multiple effects) mechanisms of action and for DNA being their primary target. In particular, anthracyclines interfere with an enzyme called "topoisomerase II," resulting in damage to the DNA of rapidly replicating tumor cells; such DNA damage leads to tumor cell death in a process called "apoptosis" (programmed cell death)
Products detail in the report…
STS has many histologic subtypes, and the malignancy can be low or high grade. Treatment may include surgery, chemotherapy, radiation therapy, or a combination of these therapies. There have been many attempts to improve the treatment outcome of locally advanced or locally relapsed disease by combining local treatment (surgery, radiotherapy) with systemic therapy, such as neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy. However, only limited data are available, supporting the use of such perioperative treatments in sarcoma. Metastasectomy and/or chemotherapy are the most common treatments offered to patients with metastatic sarcoma. Pulmonary metastasectomy, either video-assisted or through a formal thoracotomy, has been shown to increase overall survival in select populations of both osseous and STS patients. While chemotherapy remains an essential tool for the treatment of patients with metastatic sarcoma, there is mixed evidence on its survival impact.
Surgical resection of pulmonary metastases and chemotherapy are treatment options that have been employed, but many patients are poor candidates for these treatments for multiple host or tumor-related reasons. In this group of patients, radiation might provide a less morbid treatment alternative. Furthermore, many older patients, as a result of various tumor or comorbidity-related issues, are deemed poor candidates for surgery or chemotherapy. External beam radiotherapy (EBRT) has been shown to decrease local recurrence when used in conjunction with surgery for primary localized STS. The use of stereotactic body radiation therapy (SBRT) for the treatment of metastatic carcinoma to the lung has been shown to be safe and effective. Previous reports on the use of SBRT for metastatic sarcoma to the lungs exist but are limited by small patient numbers and limited long-term follow-up.
Navarria et al., 2015b, conducted a study which stated that before SBRT, 36% of patients underwent surgical resection for other lung metastases, 18% of patients received chemotherapy, and seven (25%) patients received both treatments; SBRT was performed as the first treatment in 21% patients.
The pipeline of STS with lung metastases possesses potential drugs as monotherapies as well as combination therapies.
This section provides the total STS with lung metastases market size and; market size by therapies in the United States.
The total STS with lung metastases market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total STS with lung metastases market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the STS with lung metastases market or expected to get launched in the market during the study period 2017-2030. The analysis covers the STS with lung metastases market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
STS with lung metastases Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for STS with lung metastases emerging therapies.
Reimbursement Scenario in STS with lung metastases
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the STS with lung metastases market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: